We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 13.50
High: 13.50
Low: 13.50
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

4 Apr 2024 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2024

Net asset value (“NAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2024.

B Shares

As at 31 March 2024, the unaudited NAV per B share was 63.7p.

This is a decrease of 7.0p from the audited NAV as at 31 December 2023 of 70.7p, predominantly as a result of AIM market volatility. The B share NAV as at 31 March 2024 incorporates changes in the bid prices of the B share pool’s AIM/AQSE quoted investments combined with the impact of income receivable and running costs incurred in the period. There have been no material changes in the valuations of any of the unlisted investments during the period from 31 December 2023 to the date of this announcement.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2024 was 78.7p.

Ordinary Shares

As at 31 March 2024, the unaudited NAV of an Ordinary share was 16.8p per share.

This is a decrease of 1.7p from the audited NAV as at 31 December 2023 of 18.5p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc and a decrease in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2024, shares in Scancell Holdings Plc were valued at 10.0p per share (31 December 2023: 10.5p) and shares in Arecor Therapeutics Plc were valued at 135.0p per share (31 December 2023: 180p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2024 was 90.1p.

The change in NAV for both the B Shares and Ordinary Shares represents a decrease of 0.1p per share, respectively, on the unaudited NAVs as at 20 March 2024, announced on 22 March 2024 and which was included in the Supplementary Prospectus published by the Company on 28 March 2024.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2024 and unquoted investments are carried at fair value as at 31 March 2024.

The number of B shares in issue at 31 March 2024 was 21,780,329 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 29,895,705.

The B share Offer by the Company remains open for the 2023/24 tax year until midday today, 4 April 2024 and shares will be allotted at the above latest published B share NAV.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights
18th May 20231:38 pmGNWDirectorate Changes
18th May 20231:32 pmGNWResults of Annual General Meeting Voting
3rd May 20234:01 pmGNWIssue of Equity and Total Voting Rights
27th Apr 202311:25 amGNWPublication of a Supplementary Prospectus
21st Apr 20237:00 amGNWFinal Results for the Year Ended 31 December 2022
5th Apr 20233:05 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20237:00 amGNWNet Asset Value(s)
7th Mar 20231:30 pmGNWInterim Dividend Declarations
21st Dec 20227:00 amGNWB Share Portfolio Update
7th Dec 20227:00 amGNWOrdinary Share NAV Update and Dividend Declaration
30th Nov 202212:33 pmGNWDirector/PDMR Shareholding
30th Nov 202212:29 pmGNWIssue of Equity and Total Voting Rights
19th Oct 20227:00 amGNWSecond Interim Dividend on B Shares
13th Oct 20227:00 amGNWNAV Update
26th Aug 202211:56 amGNWOffer for Subscription and Publication of Prospectus
22nd Aug 20222:53 pmGNWPDMR Shareholding
22nd Aug 20222:46 pmGNWIssue of Equity and Total Voting Rights
16th Aug 20227:00 amGNWB Share Closure of Offer for Subscription
15th Jul 20227:00 amGNWHalf-year report
30th Jun 202210:17 amGNWIssue of Supplementary Prospectus
23rd May 20227:00 amGNWAppointment of Auditor
23rd May 20227:00 amGNWShare Buy-back and TVR
4th May 202211:25 amGNWIssue of Equity and Total Voting Rights
27th Apr 20223:42 pmGNWResult of AGM
5th Apr 20221:56 pmGNWIssue of Equity and Total Voting Rights
1st Apr 20221:43 pmGNWIssue of Equity and Total Voting Rights
1st Apr 202211:05 amGNWNAV Update
25th Mar 202210:00 amGNWIssue of Supplementary Prospectus
25th Mar 20227:01 amGNWNAV Update
25th Mar 20227:00 amGNWFinal Results for the Year Ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.